SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-24-138290
Filing Date
2024-05-14
Accepted
2024-05-14 16:30:33
Documents
3
Group Members
CARLYLE HOLDINGS II GP L.L.C.CARLYLE HOLDINGS II L.L.C.CARLYLE PARTNERS VI CAYMAN HOLDINGS, L.P.CG SUBSIDIARY HOLDINGS L.L.C.TC GROUP CAYMAN INVESTMENT HOLDINGS SUB L.P.TC GROUP CAYMAN INVESTMENT HOLDINGS, L.P.TC GROUP VI CAYMAN, L.L.C.TC GROUP VI CAYMAN,

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d840145dsc13da.htm SC 13D/A 29001
2 EX-99.3 d840145dex993.htm EX-99.3 12004
3 EX-99.4 d840145dex994.htm EX-99.4 25076
  Complete submission text file 0001193125-24-138290.txt   68328
Mailing Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Business Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004 202 729 5626
Carlyle Group Inc. (Filed by) CIK: 0001527166 (see all company filings)

IRS No.: 452832612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Business Address 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121 (858) 552-1100
QuidelOrtho Corp (Subject) CIK: 0001906324 (see all company filings)

IRS No.: 874496285 | Fiscal Year End: 0101
Type: SC 13D/A | Act: 34 | File No.: 005-93684 | Film No.: 24944904
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)